0 comments Monday, November 24, 2008

Gastroesophageal reflux disease (GERD) is one of the most common gastrointestinal conditions seen in GI and primary care clinics, however physicians who treat the disease primarily rely on empirical trials of medications and their own observations and experience to manage their patients. Therefore, the American Gastroenterological Association (AGA) Institute has published evidence-based guidelines for the management and treatment of suspected GERD. The guidelines, which are the first produced through AGA's innovative guideline development process, are published in Gastroenterology, the official journal of the AGA Institute.

"There are many methods physicians are using to treat their patients with GERD, without knowing which is the best one," according to John I. Allen, MD, AGAF, chair, AGA Institute Clinical Practice and Quality Management Committee. "The AGA Institute developed this medical position statement on GERD to encapsulate the major management issues leading to consultations for the treatment of the disease to help guide physicians in treating their patients."

According to the authors, high-quality clinical trials for GERD management strategies do not exist. The majority of randomized controlled clinical trials are for pharmacologic therapies for esophageal GERD syndromes, especially acute trials for healing esophagitis. Therefore, many of the highest-level evidence-based recommendations in the guideline are for the acute treatment of heartburn or esophagitis. In developing the guidelines, the authors used the Montreal consensus definition for GERD, "a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications." Troublesome symptoms are those that adversely affect an individual's well-being.

"As we found in our research, much of the current management of patients with GERD is based on experiences from physicians, uncontrolled trials and expert opinion," according to Peter J. Kahrilas, MD, AGAF, Northwestern University's Feinberg School of Medicine and lead author of the guidelines. "We hope the development of these guidelines will help clinicians better treat patients who present with suspected GERD."

The conclusions of the technical review and medical position statement were based on the best available evidence, or in the absence of quality evidence, the expert opinions of the authors and Medical Position Panel convened to critique the technical review and structure the medical position statement. The technical review and the medical position statement together represent the guideline. The strength of the conclusions were determined using the U.S. Preventive Services Task Force grades. Grade A recommendations, which are "strongly recommended based on good evidence that it improves important health outcomes," according to the AGA Institute, include:

I. Antisecretory drugs for the treatment of patients with esophageal GERD syndromes (healing esophagitis, symptomatic relief and maintaining healing of esophagitis). In these uses, proton pump inhibitors (PPIs) are more effective than histamine receptor antagonists (H2RAs), which are more effective than placebo.

II. Long-term use of PPIs for the treatment of patients with esophagitis once they have proven clinically effective. Long-term therapy should be titrated down to the lowest effective dose based on symptom control.

III. When antireflux surgery and PPI therapy are judged to offer similar effectiveness in a patient with an esophageal GERD syndrome, PPI therapy should be recommended as initial therapy because of superior safety.

IV. When a patient with an esophageal GERD syndrome is responsive to, but intolerant of, acid suppressive therapy, antireflux surgery should be recommended as an alternative.

V. Twice-daily PPI therapy as an empirical trial for patients with suspected reflux chest pain syndrome after a cardiac etiology has been carefully considered.

Other recommendations include grade B - "recommended with fair evidence that it improves important outcomes;" grade C - "balance of benefits and harms is too close to justify a general recommendation;" grade D - recommend against, fair evidence that it is ineffective or harms outweigh benefits;" and grade insufficient - "no recommendation, insufficient evidence to recommend for or against."

To develop the guidelines, a set of 12 broad questions were identified by experts in the field to encapsulate the most common management questions faced by clinicians. To review recommendations and grades, view the AGA Medical Position Statement of the Management of Gastroesophageal Reflux Disease. The guidelines were developed through interaction among the authors, the AGA Institute, the Clinical Practice and Quality Management Committee and representatives from the AGA Institute Council.

Source:
Aimee Frank
American Gastroenterological Association

1 comments

For many people, Thanksgiving is about having family near and celebrating, sometimes in excess. That's because for some holiday revelers, perhaps the amount of time spent watching football on the tube is only surpassed by a second activity: eating. And with the turkey, sweet potatoes and pumpkin pie comes heartburn, but how do you know if you have a simple case of it, or something more serious? Simply put, if the heartburn you have affects your quality of life, you may have gastro-esophagael reflux disease, more commonly known as GERD.

"If a person has a burning feeling down in their gut that goes up into the chest, made worse by eating, or exercising or lying down, and this happens several times a week, then that's affecting their life and there's a good chance they have GERD,"said gastroenterologist Joel Richter, M.D., chair of the Department of Medicine at Temple University School of Medicine. "The next step is to see a doctor and have the condition evaluated because there is actually "good" and "bad" GERD."

And how doctors treat the two types are very different. Richter says "good" GERD is the most common; about 80 to 90 percent of patients have it. This group may have occasional to daily heartburn symptoms, but nothing more serious, such as esophageal damage by endoscopy or problems with swallowing.

"For this group, more medication may not be the answer. Rather," says Richter. "Those with intermittent symptoms need to modify their lifestyle by losing weight,reducing their fat intake and not eating late at night before going to bed."

And while they can take proton pump inhibitors, (PPI's) which ease heartburn by alleviating excess stomach acid that flows back into the esophagus, Richter recommends that many will only need to take these pills as needed when their symptoms are bothersome. But for the second group of sufferers who have "bad" or more serious GERD symptoms, a lifetime drug therapy regimen can not only improve their quality of life, but can be life-saving.

"About 10 to 15 percent of GERD patients suffer from a more severe form, in which they have scarring on the esophagus, problems swallowing, and may even have Barrett's Esophagus, in which the cells lining the esophagus can turn cancerous," said Richter. "So, even though PPI's pose the risk of side effects, they are very effective for this group and the benefits of using them far outweigh the risks."

Patients who rely on these drugs when they're not needed put themselves at unnecessary risk for side effects when used long-term, which include an increase in bacterial pneumonia, gastrointestinal infections, and hip fractures, especially in women. Richter warns that before a patient starts self-medicating with PPI's, it's crucial that they find out which type of GERD they're suffering from. The best way to do that is through a set of consults with a doctor. An initial visit will consist of an endoscopy and a review of the patient's medical history to determine what type of pill a patient should be on. A follow up visit to evaluate the patient's response to the drug determines which type of GERD they have.

"These visits are the two pieces to the puzzle when diagnosing someone with GERD," said Richter.

Temple University
301 University Services Bldg.1601 N Broad St.
Philadelphia
PA 19122
United States
http://www.temple.edu

3 comments

caAccording to the American Cancer Society (ACS), more than 16,000 new esophageal cancer cases are diagnosed each year in the U.S. Unfortunately the survival rate in these cases is only 10 percent. This alarming statistic is due largely to the fact that by the time the majority of cases are diagnosed, the cancerous tumors have grown to the point of inoperability. Raising patient awareness about potential conditions that, if left untreated, could progress into esophageal cancer, will encourage patients to seek the appropriate care through their physician.

Many people are aware that tobacco use increases the risk of developing esophageal cancer; however, there are several other common contributing risk factors including:

- Excessive alcohol consumption;
- Obesity;
- Lye ingestion; and,
- Gastroesophageal reflux disease (GERD), also known as acid reflux or heartburn.

A recent ACS Gallup poll revealed that 44 percent of adults in the U.S. have heartburn at least once per month and that approximately 30 percent of esophageal cancer cases can be linked to GERD. GERD is a condition in which acid (with some pepsin and bile) splashes up from the stomach into the esophagus. These three fluids are potentially dangerous to the sensitive esophageal tissue, as they can inflame and damage the lining of the esophagus, a condition known as esophagitis.

If GERD becomes a chronic condition, it can develop into Barrett's esophagus, a precursor to esophageal cancer. Barrett's esophagus is a condition in which the color and composition of the cells lining the lower esophagus change due to repeated exposure to stomach acid. Only a small percentage of people with GERD develop Barrett's esophagus, but once it is diagnosed, patients should be sure to meet with their physician regularly as they are at a greater risk of developing esophageal cancer.

Symptoms of advanced GERD or the presence of Barrett's esophagus include:

- Frequent heartburn. A burning-type pain in the lower part of the mid-chest, behind the breast bone, and in the mid-abdomen.
- Difficulty swallowing. Often, a narrowing of the esophagus (esophageal stricture) leads to trouble swallowing or dysphagia.
- Bleeding. A person may vomit red blood or blood that looks like coffee grounds, or your stools may be black, tarry or bloody.
- Weight loss and loss of appetite.

According to the ACS, prevention of Barrett's esophagus can begin with controlling GERD by making some simple lifestyle changes, such as:

- Losing weight. Obesity increases abdominal pressure, which can then push stomach contents up into the esophagus;
- Eating a diet full of fruits and vegetables, eating smaller and more frequent meals and not eating two to three hours prior to bedtime;
- Smoking cessation, as nicotine relaxes the esophageal sphincter and smoking also stimulates the production of stomach acid;
- Discontinuing the consumption of alcohol.

People with severe GERD and Barrett's esophagus often require aggressive treatment and prevention methods including medications, other nonsurgical medical procedures such as endoscopic therapies, or even laparoscopic and open surgeries. Often times, swallowing difficulty (known as dysphagia) and other symptoms can be treated if identified early.

However, due to the aggressive nature of the disease, the majority of patients who have esophageal cancer are not surgical candidates. In these situations, the primary focus becomes palliative care - providing comfort measures to help maintain quality of life. This includes treating the dysphagia and restoring the patient's ability to swallow food and drink liquids by opening the stricture within the esophagus.

To open the barriers caused by tumor in-growth physicians use an esophageal metal stent. Prior to the stent placement the patient may require dilation of the stricture to allow room for the stent to be positioned, thereby expanding the lumen of the esophagus. Traditionally, the placement of the stent can be a painful process for the patient, yet new technologies are making this procedure easier on the patient and physician.

New, innovative delivery systems enable accurate deployment and recapturability of the stent. This reduces the stent from moving or migrating into the stomach and thus the need for repeat procedures to replace or reposition the stent, one of the more common complications in traditional esophageal stenting.

Raising awareness about the primary pre-cursors to esophageal cancer - GERD and Barrett's esophagus - will encourage patients with these conditions to consult their physicians for the necessary screenings and treatment options. However, when palliative care becomes the primary option for patients with esophageal cancer, recent advancements in medical device technologies enable physicians to more easily implant an esophageal stent and in turn improve patients' quality of life.

Medicalnews

0 comments Monday, August 11, 2008

People who have gastrointestinal (GI) bleeding after a stroke are more likely to die or become severely disabled than stroke sufferers with no GI bleeding, according to a study published in the August 6, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology.

"This is an important finding since there are effective medications to reduce gastric acid that can lead to upper gastrointestinal bleeding," said study author Martin O'Donnell, MB, of McMaster University in Hamilton, Ontario. "More research will be needed to determine whether this is a viable strategy to improve outcomes after stroke in high-risk patients."

The study involved 6,853 people who had ischemic strokes. The most common type of stroke, ischemic strokes occur when blood flow to the brain is reduced or blocked. Of those, 829 people died during their hospital stay and 1,374 had died within six months after the stroke.

A total of 100 people, or 1.5 percent, had gastrointestinal bleeding, or bleeding in the stomach or intestines, while they were in the hospital from the stroke. In more than half of the cases, the GI bleeding occurred in people who had mild to moderate strokes.

The people with GI bleeding were more than three times more likely to die during their hospital stay or be severely dependent on others for their care at the time they left the hospital than people who did not have GI bleeding. A total of 81 percent of those with GI bleeding died in the hospital or were severely dependent, compared to 41 percent of those without GI bleeding.

Those with GI bleeding were also 1.5 times more likely to have died within six months after the stroke than those without GI bleeding. Of those with GI bleeding, 46 percent had died within six months, compared to 20 percent of those without GI bleeding. This relationship remained even after researchers adjusted for other factors, including other conditions such as pneumonia and heart attack.

The study was supported by the Canadian Stroke Network, the Ontario Ministry of Health and Long-term Care, the Canadian Institutes of Health Research, the Institute for Clinical Evaluative Sciences and the University Health Network Women's Health Program in Toronto.

The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer's disease, epilepsy, Parkinson's disease, and multiple sclerosis.

For more information about the American Academy of Neurology, visit http://www.aan.com.

0 comments

Researchers at Duke University Medical Center appear to have solved at least a piece of a puzzle that has mystified physicians for years: why so many patients with asthma also suffer from GERD, or gastroesophageal reflux disease.

Clinicians first noted a relationship between the two diseases in the mid-1970s. Since then, studies have shown that anywhere from 50 to 90 percent of patients with asthma experience some aspect of GERD. But can GERD cause asthma, or, is it the other way around? Perhaps there is some shared mechanism at the root of both disorders causing them to arise together. Physicians could make a case for each scenario, but until now, the exact nature of the relationship was not clear.

Working in laboratory experiments with mice, Dr. Shu Lin, an assistant professor of surgery and immunology at Duke, discovered that inhaling tiny amounts of stomach fluid that back up into the esophagus - a hallmark of GERD - produces changes in the immune system that can drive the development of asthma.

In the experiments, researchers inserted miniscule amounts of gastric fluid into the lungs of mice (mimicking the human process of micro-aspiration, or breathing in tiny amounts) over a period of eight weeks. They compared these animals' immune systems with those of mice that were exposed to allergens but not the gastric fluid.

The immune systems of the two sets of mice responded very differently. Those that had the gastric fluid in their lungs developed what researchers call a T-helper type 2 response, a type of immune system reaction characteristic of asthma. The other mice responded in a more balanced manner, mounting an immune reaction consisting of both T-helper type 1 and T-helper type 2 responses.

"This is the first experimental evidence in a controlled, laboratory setting linking these two very common conditions in humans," says Lin, the senior author of the study published online in the European Journal of Clinical Investigation. "These data suggest that chronic micro-aspiration of gastric fluid can drive the immune system toward an asthmatic response."

"This does not mean that everyone with GERD is going to develop asthma, by any means," says William Parker, an assistant professor of surgery at Duke and a co-author of the study. "But it may mean that people with GERD may be more likely to develop asthma. If there is an upside to this, it is that developing GERD is something we can pretty much treat and control."

Parker says poor diet, a lack of exercise and obesity all contribute to the development of GERD, and that rising rates of reflux disease are part of a "perfect storm" of environmental and behavioral factors driving escalating rates of asthma, particularly in Western cultures. "People should avoid the risk factors for GERD. We strongly believe that the rise in asthma, particularly among adults in the country, is in large measure due to lifestyle choices that can be changed."

Lin and Parker agree that much more work needs to be done to fully understand the cellular and molecular mechanisms involved in the relationship between reflux disease and asthma, but both feel their study offers new directions for developing additional treatment options for both problems.

Lin says patients who already have GERD can minimize gastric reflux - and thereby lessen their chances of developing asthma - by following a few simple guidelines: Eat smaller meals and eat several hours before going to bed; raise the head of the bed a few inches; maintain a healthy weight; and limit fatty foods, coffee, tea, caffeine and alcohol - they can relax the esophageal sphincter and make reflux more likely.

Source: Michelle Gailiun
Duke University Medical Center

0 comments

Researchers at The Evergreen State College in collaboration with the U.S. Department of Agriculture at Texas A&M have been working to increase food safety by reducing the populations of E. coli in the guts of sheep and cattle. The goal of the research is to increase understanding of the complex predator-prey relationship between bacteria (the prey) and bacteriophages (the viral predator). The research could lead to safer food.

E. coli O157:H7 is a dangerous bacterial food pathogen that occurs naturally in the guts of livestock without making them sick. E. coli is easily passed from farm animals to humans. The bacterium causes food poisoning, sickness, and sometimes death in people who eat tainted meat or contaminated produce or water.

Andrew Brabban and Betty Kutter, microbiologists at Evergreen State College in Olympia, Washington, have been studying tiny E. coli predators known as bacteriophages, which attack E. coli bacteria. The Evergreen State phage biology lab was established in 1973 and together Kutter and Brabban have more than six decades of research experience on phages.

Brabban, Kutter, and colleagues have uncovered bacteriophages that attack various strains of E. coli naturally in cattle or sheep's stomach. Recent results appeared under the title "Prevalence of Escherichia coli O157 and O157:H7-infecting bacteriophages in feedlot cattle feces" in the October issue of Letters in Applied Microbiology. The research is funded by the U.S. National Institutes of Health, Phage Biotics, the National Cattlemen's Beef Association and the U.S. Department of Agriculture.

By using phage as a natural predator, it may be possible to better target and tame E. coli and increase the safety of food. Using bacteriophages provides a potentially cheap and broadly applicable way to treat cattle that offers advantages over traditional antibiotics.

Phage treatment is more specific to E. coli, which means it is less likely to encourage resistance in other harmful bacteria and less likely to kill useful bacteria. Also, much like the bacteria, the bacteriophage is easily transferred from one infected individual to another, resulting in a more robust solution to E. coli infections.

Economic impacts could also be significant. "E. coli contamination results in waste of meat, and ultimately wasted meat costs consumers," says Brabban. "Hundreds of millions are also spent to treat E. coli infections," he adds.

But while economics are important, healthier food is the top priority of the research. "It would be very rewarding if we could come up with an increased understanding or an application that leads to safer food down the line," says Brabban. "We all would like food to be safer."

The Evergreen State College
http://www.evergreen.edu

0 comments

A pre-cancerous condition linked to chronic acid reflux often gets overlooked. Can the medical community do a better job intervening? Researchers from the Hutchinson-MRC Research Centre in Cambridge think so.

In a review published in the inaugural issue of Disease Models & Mechanisms (DMM), experts on a disease known as "Barrett's oesophagus" discuss how "Barrett's" presents unique challenges in diagnosis and treatment. They cite key factors which make this illness difficult to detect, and suggest how scientists and doctors can team up to improve the odds of intervention.

Doctors want to understand more about this condition because patients with Barrett's have 30 to 125 times increased risk of an often fatal cancer of the oesophagus. One of the most common indicators of Barrett's is severe and chronic acid reflux. The authors of the review article discuss several reasons why most Barrett's cases are undiagnosed. The wide-spread availability of over-the-counter antacid medications may contribute by suppressing symptoms such that only the most severe and persistent cases of acid reflux are recommended for screening. Additionally, in order to screen for Barrett's, the oesophagus must be examined with a small light and camera (endoscope) which is not a routine procedure.

The biological basis of Barrett's is an abnormal change, or dysplasia, in the oesophagus. Normally, the oesophagus is lined with flat-shaped cells known as squamous cells. However, in patients with Barrett's, the cell lining consists of rectangular-shaped columnar cells. This process of normal cells morphing into abnormal cells is common to several types of cancer, not just oesophageal cancer. Thus, a greater understanding of Barrett's can also lead to potential therapies for similar pre-cancerous conditions.

In order to advance the diagnosis of Barrett's oesophagus, researchers recommend identifying standardized indicators which can be used to identify the presence of Barrett's as well as predict the likelihood that it will progress into cancer. Additionally, they recommend developing less costly screening methods to allow routine checks for Barrett's in patients with acid reflux. They point out the need for developing laboratory animal models of this disease in order to study the underlying molecular mechanisms of Barrett's, as well as to test potential novel therapies.

The review was written by Massimilian di Pietro, Christopher J. Peters and Rebecca C. Fitzgerald of the Hutchinson-MRC Research Centre in Cambridge, UK. The report was published in the inaugural July/August issue of a new research journal, Disease Models & Mechanisms (DMM), published by The Company of Biologists, a non-profit based in Cambridge, UK.

The DMM website is located at: http://dmm.biologists.org